Skip to main content

Doximity, Inc. (DOCS) Stock Analysis

Recovery setup · Catalyst-Driven edge

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Health Information Services

Sell if holding. Engine safety override at $24.81: Risk below floor (2.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.18; Below long-term trend.

Doximity is the leading digital platform for U.S. medical professionals with over 2 million registered members including 80%+ of U.S. physicians. Revenue from pharmaceutical manufacturers and health systems paying for Marketing, Hiring, and Workflow Solutions grew 20% in fiscal... Read more

$24.81+36.8% A.UpsideScore 5.6/10#7 of 13 Health Information Services
Stop $23.11Target $34.00(analyst − 10%)A.R:R 2.5:1
Analyst target$37.77+52.2%22 analysts
$34.00our TP
$24.81price
$37.77mean
$55

Sell if holding. Engine safety override at $24.81: Risk below floor (2.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.18; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 65. Score 5.6/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Risk below floor (2.9 < 3.0)

Key Metrics

P/E (TTM)20.5
P/E (Fwd)15.1
Mkt Cap$4.6B
EV/EBITDA15.4
Profit Mgn37.5%
ROE23.8%
Rev Growth9.8%
Beta1.42
DividendNone
Rating analysts30

Quality Signals

Piotroski F7/9

Options Flow

P/C2.18bearish
IV134%elevated
Max Pain$13-49.6% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerpharmaceutical manufacturer customers
    10-K Item 1A: 'We do not typically enter into long-term contracts with our pharmaceutical manufacturer customers, who represent a significant portion of our revenue'

Material Events(8-K, last 90d)

  • 2026-04-17Item 5.02HIGH
    CFO Anna Bryson resignation accepted April 13, 2026 (had been on medical leave since February 3, 2026). Siddharth Sitaram continues as interim CFO. Company conducting search; no permanent successor named.
    SEC filing →
  • 2026-02-05Item 5.02HIGH
    CFO Anna Bryson placed on medical leave effective February 3, 2026. Siddharth Sitaram (Chief Accounting Officer) appointed interim principal financial officer. No permanent successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Support Resistance
1.6
Bollinger
2.2
Gap
5.0

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
5.0

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Put Call
0.0
Implied Vol
0.0
Volatility
0.9
Max Pain Risk
3.0
Short Interest
4.2
Debt Equity
4.8
Days To Cover
5.2
Beta
5.3
Elevated put/call: 2.18High IV: 134%Above max pain $12
GatesMomentum 4.1<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 12d<=14d (soft)A.R:R 2.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
65 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $20.55Resistance $25.65

Price Targets

$23
$34
A.Upside+37.0%
A.R:R2.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Risk below floor (2.9 < 3.0)
! Momentum score 4.1/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-13 (12d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is DOCS stock a buy right now?

Sell if holding. Engine safety override at $24.81: Risk below floor (2.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.18; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 65. Prior stop was $23.11. Score 5.6/10, moderate confidence.

What is the DOCS stock price target?

Take-profit target: $34.00 (+36.8% upside). Prior stop was $23.11. Stop-loss: $23.11.

What are the risks of investing in DOCS?

Risk below floor (2.9 < 3.0).

Is DOCS overvalued or undervalued?

Doximity, Inc. trades at a P/E of 20.5 (forward 15.1). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about DOCS?

30 analysts cover DOCS with a consensus score of 4.1/5. Average price target: $38.

What does Doximity, Inc. do?Doximity is the leading digital platform for U.S. medical professionals with over 2 million registered members...

Doximity is the leading digital platform for U.S. medical professionals with over 2 million registered members including 80%+ of U.S. physicians. Revenue from pharmaceutical manufacturers and health systems paying for Marketing, Hiring, and Workflow Solutions grew 20% in fiscal 2025. Network effects create a moat as member scale drives physician engagement and increases value to marketing customers.

Related stocks: WAY (Waystar Holding Corp.) · HQY (HealthEquity, Inc.) · VEEV (Veeva Systems Inc.) · PRVA (Privia Health Group, Inc.) · HNGE (Hinge Health, Inc.)